13 Stocks That Crossed Jim Cramer’s Radar 

Page 8 of 12

5. Medtronic plc (NYSE:MDT)

Number of Hedge Fund Holders In Q2 2025: 62

Medtronic plc (NYSE:MDT) is a medical technology company that makes and sells devices for cardiovascular, neuroscience, and surgical applications. Cramer has discussed the firm on a handful of occasions in 2025. One such discussion occurred in May, when the CNBC TV host called the stock “inconsistent” despite Medtronic plc (NYSE:MDT) delivering strong numbers. The firm’s latest earnings report came earlier this week and saw it increase its fiscal year 2026 revenue growth to 5.5% and its EPS guidance to $5.62 – $5.66 per share. Medtronic plc (NYSE:MDT)’s $9 billion in fiscal second-quarter revenue and $1.36 in earnings also beat analyst estimates as CEO Geoffrey Martha attributed the performance to the overall strength in medical procedures. Cramer discussed the firm’s CEO and its businesses:

“What does the market like? Well it likes Merck on the Winrevair trial. Obviously we know it likes Amgen, you’re a high. But it loves Medtronic. . .Geoffrey Martha is one of the finest people I’ve ever met and I’ve been waiting for the earnings explosion. Well we got it today, and I think that, believe it or not, even up here, it’s a buy. Because they’ve got a series of like, where they are with ablations. Where they are with diabetes, which are spinning off. Their cardiovascular really is second to none. I am finally so gratified about their neuroscience. Which I have worked with them to be able to say, look, guys you have to make breakthroughs, in the toughest area, neuroscience, and I told Geoff, personally, I said I need this. And he, committed, and he’s delivered. He’s quite a man. And this is good stuff.

“[Responding to David’s comment about share price movement] They have reverse head and shoulders I know you care. But I am so impressed, with what they’ve done. And I’ve got to tell you, they are, when they get the diabetes business separated, cause I don’t like the diabetes business, the stock is going to trade up even more.

“[After David asked if he believes the stock’s got more to go through after the separation] Oh, I do believe this is the breakout I’ve been waiting from Geoff, he delivered, and he’s a sensational guy who cares tremendously about patients [inaudible].”

The latest remarks represent Cramer’s continued optimism for Medtronic plc (NYSE:MDT) as he had commented in January:

“Medtronic is doing so many things, they’re going to have mid single digit growth, I really like them.”

Page 8 of 12